Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.

Détails

Ressource 1Demande d'une copie Sous embargo indéterminé.
Accès restreint UNIL
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_F69D11E34A2A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Spatial Distribution of Recurrence and Long-Term Toxicity Following Dose Escalation to the Dominant Intra-Prostatic Nodule for Intermediate-High-Risk Prostate Cancer: Insights from a Phase I/II Study.
Périodique
Cancers
Auteur⸱e⸱s
Cloître M., Benkhaled S., Boughdad S., Schaefer N., Prior J.O., Zeverino M., Berthold D., Tawadros T., Meuwly J.Y., Martel P., Rohner C., Heym L., Duclos F., Vallet V., Valerio M., Bourhis J., Herrera F.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Statut éditorial
Publié
Date de publication
31/05/2024
Peer-reviewed
Oui
Volume
16
Numéro
11
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Objectives: We investigated spatial patterns between primary and recurrent tumor sites and assessed long-term toxicity after dose escalation stereotactic body radiation therapy (SBRT) to the dominant intra-prostatic nodule (DIN). Materials and methods: In 33 patients with intermediate-high-risk prostate cancer (PCa), doses up to 50 Gy were administered to the DIN. Recurrence sites were determined and compared to the original tumor development sites through multiparametric MRI and <sup>68</sup> Ga-labeled prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography ( <sup>68</sup> Ga-PSMA-PET/CT) images. Overlap rates, categorized as 75% or higher for full overlap, and 25-74% for partial overlap, were assessed. Long-term toxicity is reported. Results: All patients completed treatment, with only one receiving concomitant androgen deprivation therapy (ADT). Recurrences were diagnosed after a median of 33 months (range: 17-76 months), affecting 13 out of 33 patients (39.4%). Intra-prostatic recurrences occurred in 7 patients (21%), with ≥75% overlap in two, a partial overlap in another two, and no overlap in the remaining three patients. Notably, five patients with intra-prostatic recurrences had synchronous bone and/or lymph node metastases, while six patients had isolated bone or lymph node metastasis without intra-prostatic recurrences. Extended follow-up revealed late grade ≥ 2 GU and GI toxicity in 18% (n = 6) and 6% (n = 2) of the patients. Conclusions: Among patients with intermediate-high-risk PCa undergoing focal dose-escalated SBRT without ADT, DIN recurrences were infrequent. When present, these recurrences were typically located at the original site or adjacent to the initial tumor. Conversely, relapses beyond the DIN and in extra-prostatic (metastatic) sites were prevalent, underscoring the significance of systemic ADT in managing this patient population. Advances in knowledge: Focal dose-escalated prostate SBRT prevented recurrences in the dominant nodule; however, extra-prostatic recurrence sites were frequent.
Mots-clé
Sbrt, dosimetry analysis, intermediate–high-risk, pattern of recurrence, prostate cancer, stereotactic treatment, SBRT
Pubmed
Web of science
Open Access
Oui
Création de la notice
21/06/2024 10:07
Dernière modification de la notice
02/07/2024 8:37
Données d'usage